Clinical trial
A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
NCT03578809 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 5, 2018
- Completion date
- January 18, 2021
- Enrollment
- 593 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.